In the high-stakes world of biotechnology, the lifecycle of a company is often defined by its exits. However, for the leadership team behind Actio Biosciences, the $1.3 billion sale of their core epilepsy program to Jazz Pharmaceuticals in August was not an ending, but a pivot point. Two months after that landmark transaction, the team has re-emerged with a new identity: Setara Biosciences.
Launched officially this Friday with a robust $90 million in financing, Setara is tasked with the mission of advancing the remainder of Actio’s innovative pipeline. The company is setting its sights on some of medicine’s most stubborn challenges, including Charcot-Marie-Tooth (CMT) disease, overactive bladder, and a suite of discovery-stage programs targeting rare neurological conditions.
The Genesis of Setara: A New Chapter for Ion Channel Therapeutics
The formation of Setara Biosciences represents a deliberate strategy to preserve the intellectual capital and scientific focus developed under the Actio banner. While the acquisition by Jazz validated the "genetics-first" philosophy of CEO David Goldstein, the team behind the scenes felt that the remaining pipeline held too much potential to be sidelined or absorbed into a larger, less agile corporate structure.
"We didn’t start all this to just sell everything for whoever is willing to buy it for a certain price," Goldstein noted in a recent interview. "A small, laser-focused biotech is, in my view, the best environment to do this kind of early-stage work."
Setara, whose name is derived from the Farsi word setar (star), aims to leverage the same platform that made Actio a target for acquisition. By focusing on ion channels—the "microscopic gateways" that regulate electrical signals in the body—the company is positioning itself to address the underlying genetic drivers of complex diseases.
Chronology: A Trajectory of Growth and Strategic Divestment
To understand the emergence of Setara, one must look at the rapid evolution of its predecessor, Actio Biosciences.
- Early Foundations: Actio was built on a platform designed to identify rare genetic mutations and develop therapies that "reset" cellular activity. Their initial success centered on KCNT1 mutations, which are linked to severe, treatment-resistant epilepsies.
- August 2024 (The Jazz Deal): Jazz Pharmaceuticals, looking to bolster its neurological footprint, acquired Actio in a deal valued at $1.3 billion. The acquisition centered specifically on Actio’s KCNT1 program, which aims to block malfunctioning proteins that trigger seizures.
- October 2024 (The Launch of Setara): With the capital from the acquisition and the continued support of major venture backers, the core team—led by Goldstein, CSO David Breckenridge, and CFO Cayce Denton—formed Setara Biosciences to manage the remaining assets.
- The Immediate Future: Setara is currently preparing for a Phase 1b clinical trial of its lead candidate, STAR-0871, expected to commence by the end of the year.
The Science: Targeting the TRPV4 Ion Channel
At the heart of Setara’s portfolio is STAR-0871, a small-molecule drug designed to inhibit the TRPV4 ion channel. Ion channels have become a "holy grail" of modern pharmacology. As seen with the success of Vertex Pharmaceuticals’ cystic fibrosis treatments, targeting these tiny protein tunnels can effectively treat diseases that were previously thought to be unmanageable.
In the context of Charcot-Marie-Tooth (CMT) disease, specifically the "type 2C" variant, these channels become overactive, leading to the nerve damage and muscle atrophy that define the condition.
"The goal is to take a mutant channel that’s overactive and push its activity back down to, or below, wild-type levels," Goldstein explained. By normalizing this activity, Setara hopes to not just treat the symptoms of CMT, but to fundamentally alter the progression of the disease.
The Challenge of Measuring Success
Developing a drug for CMT is significantly more complex than developing one for epilepsy. As Goldstein points out, epilepsy has a "clear, objective metric": the frequency of seizures. In contrast, CMT is a slow-progressing, multifaceted disorder. Patients experience varying degrees of limb weakness, vocal cord dysfunction, and respiratory complications.
"You have a variety of muscle groups that get weaker and compromise function in complicated ways," Goldstein said. "Then you have the question of what’s the best way to assess the impact of the disease and whether therapy is improving it."
Setara’s approach to solving this includes sophisticated biomarker analysis and long-term functional assessments that seek to quantify subtle improvements in nerve health that might otherwise go unnoticed in traditional clinical trials.
Supporting Data: Diversification into Overactive Bladder
While CMT remains the flagship indication for STAR-0871, Setara is not pinning its entire valuation on a single rare disease. The company is also initiating a Phase 2 study of STAR-0871 for overactive bladder (OAB).
This is a strategic move that addresses a massive, underserved patient population. Tens of millions of people in the United States suffer from OAB, and the biological commonalities between the overactive nerve signaling in CMT and the overactive muscle signaling in OAB are striking. By repurposing its lead asset, Setara is hedging its bets and demonstrating the versatility of its ion-channel-modulating platform.
Official Responses and Investor Confidence
The transition from Actio to Setara has been met with a high degree of confidence from the investment community. Many of Actio’s original backers, including Deerfield Management and Canaan, have doubled down on the new entity. Notably, Jazz Pharmaceuticals has retained a minority stake in Setara, effectively keeping a "foot in the door" should Setara’s remaining pipeline prove as successful as the KCNT1 program.
Jason Fuller, a partner at Deerfield Management, emphasized that the transition is not merely a reshuffling of assets, but a validation of the underlying science. "We believe that Actio’s acquisition by Jazz validates the genetics-driven approach to drug discovery and development that underpins Setara," Fuller said.
This sentiment is echoed by the team at Setara, who believe the structure of the new company allows for a level of scientific agility that is often lost in larger pharmaceutical conglomerates. By remaining lean and focused, the company hopes to shorten the distance between the laboratory bench and the patient bedside.
Implications for the Rare Disease Landscape
The debut of Setara Biosciences highlights a growing trend in biotech: the "deconstruction" of pipelines into focused, mission-driven companies. By offloading late-stage or highly commercialized programs to established Big Pharma players, nimble biotech firms are increasingly able to spin off their more "experimental" or "high-risk" assets into independent entities with fresh capital and renewed focus.
This model has several key implications:
- Capital Efficiency: By spinning off, Setara avoids the overhead and bureaucratic friction of a large organization, allowing the $90 million in funding to be directed almost exclusively toward R&D.
- Specialization: By focusing on ion channels, Setara can build a proprietary "knowledge base" that makes their discovery-stage programs in epilepsy, migraines, and rare diseases more likely to succeed.
- Risk Mitigation: For investors, this structure provides a clear path to value creation. Instead of waiting for a single, monolithic company to succeed or fail, they can participate in the specific successes of individual programs.
As Setara moves toward its first clinical milestones, the industry will be watching closely. If STAR-0871 proves effective in treating the complex, slow-moving pathology of CMT, it will not only provide a life-changing treatment for a neglected patient population but will also cement the "spin-off" model as a superior way to cultivate breakthrough innovation in an era of pharmaceutical consolidation.
For now, the team at Setara is focused on the task at hand: turning the potential of ion-channel inhibition into a tangible medical reality. In the words of Goldstein, the path forward is clear: "We are building something that is meant to last, to go deep into the biology, and to solve problems that others have found too difficult to measure."
About the Author
